Lorundrostat: Results from Advance-HTN Phase 2 Study

Luke Laffin, MD, shares the findings from a late breaker he presented at ACC 2025. Lorundrostat is an investigational drug found to significantly lower 24-hour blood pressure among patients with uncontrolled and resistant hypertension. Learn more about C5 Research at Cleveland Clinic.https://my.clevelandclinic.org/research/c5researchLooking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.